netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
Notes:

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

 Details...
01.05.02  Expand sub section  Corticosteroids
Beclometasone MR tabs (Clipper® - licensed use)
View adult BNF View SPC online
Restricted Drug Restricted
Amber 1

Second-line option (after prednisolone tabs) for active mild or moderate ulcerative colitis

  • As add-on to 5-ASA in patients who have insufficient response to 5-ASA, or
  • As monotherapy where 5-ASA and prednisolone are contraindicated or not tolerated (off-label)
  • Maximum course length = 4 weeks
 
   
Budesonide controlled release caps (Entocort®)
View adult BNF View SPC online
Formulary

Controlled release caps are only licensed for induction of remission in Crohn's disease

  • Dose = 9mg daily
  • Usual course length = 4-6 weeks
 
   
Budesonide orodispersible tabs (Jorveza® - eosinophilic oesophagitis)
View adult BNF View SPC online
Formulary
Red

Approved for induction of remission in eosinophliic oesophagitis after failure of a PPI

6 week to 12 week course only. Maintenance use is non-formulary.

 
   
Budesonide rectal foam
View adult BNF View SPC online
Formulary

 
   
Hydrocortisone foam enema
View adult BNF
Formulary

 
   
Prednisolone tabs, retention enema, rectal foam, suppositories
View adult BNF View SPC online
Formulary Prednisolone enteric coated tablets are non-formulary 
   
Beclometasone MR tabs (Clipper® - Graft vs Host Disease - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Treatment of acute intestinal Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy 16069/P

  • Approved for short courses and dosing in line with licensed use in inflammatory bowel disease
 
Link  NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
   
Budesonide controlled release caps, gastroresistant caps (Entocort®, Budenofalk® - Graft vs Host Disease - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Treatment of acute intestinal Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy 16069/P

Approved for short courses and dosing in line with licensed use in inflammatory bowel disease

 
Link  NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
   
01.05.02  Expand sub section  Oral
01.05.02  Expand sub section  Topical
01.05.02  Expand sub section  Parenteral
Triamcinolone acetonide injection (oesophageal stricture - off-label)
View adult BNF View SPC online
Formulary
Red
Approved off-label indication:
Management of refractory oesophageal stricture (intralesional endoscopic injection)
  • For use in patients refractory to standard dilatation
  • Consultant gastroenterologist use only
  • Dose = 40 mg to 80 mg 
  •    
     ....
     Non Formulary Items
    Budesonide prolonged release tabs  (Cortiment®)

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not recommended for prescribing in South East London

     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

    Green

    Specialist and non-specialist initiation  

    Grey

    Not recommended for prescribing  

    netFormulary